Evidence map›Paper›PMID 38243631›Full record

ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2024

Recent trends in disease-modifying therapy use and associated sickness absence and disability pension among people with multiple sclerosis in Sweden.

Fitsum Sebsibe Teni, Alejandra Machado, Katharina Fink, Hanna Gyllensten, Jan Hillert, Emilie Friberg

Abstract read
In one paragraph

Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Family planning and multiple sclerosis - Part 1: Patient perspectives on treatment choices in Sweden.Multiple sclerosis journal - experimental, translational and clinical
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fitsum Sebsibe TeniDivision of Insurance Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-6182-499X
Alejandra MachadoDivision of Insurance Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-8957-661X
Katharina FinkDivision of Neurology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Hanna GyllenstenInstitute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0001-6890-5162
Jan HillertDivision of Neurology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-7386-6732
Emilie FribergDivision of Insurance Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDisease-modifying therapies (DMTs) have led to improved health and work productivity among people with multiple sclerosis (PwMS).

objectivesTo describe trajectories of recent DMT use and their association with sickness absence and/or disability pension (SADP) among PwMS in Sweden.

methodsA longitudinal register-based study was conducted among 1395 PwMS with treatment start in 2014/2015. While DMT use over 5 years was assessed using sequence analysis resulting in four clusters, a 7-year (Y

resultsFour clusters of DMT use trajectories were identified:

conclusionUsing sequence analysis, this study showed recent DMT use trajectories among PwMS where initiation of high-efficacy DMTs has become more common. The trend of SADP was stable and lower in those using non-high-efficacy DMTs and larger improvements were shown in those initiating high-efficacy DMTs.

Indexed as

AzidesMultiple SclerosisHumansLongitudinal StudiesPensionsSweden3-((4-azidophenyl)dithio)propionic N-hydroxysuccinimideAzidescluster analysisDisease-modifying drugshigh-efficacy DMTssick leave

Identifiers

PMID38243631
PMCPMC10935615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.